Neurocrine Biosciences Financial Statements (NBIX)
|
|
|
|
Report date
|
|
|
05.05.2025 |
30.07.2025 |
28.10.2025 |
11.02.2026 |
05.05.2026 |
|
05.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
572.6 |
687.5 |
794.9 |
805.5 |
814.5 |
|
3 102 |
|
Operating Income, bln rub |
|
|
23.6 |
145.6 |
239.0 |
210.9 |
186.0 |
|
781.5 |
|
EBITDA, bln rub |
? |
|
31.3 |
152.9 |
299.5 |
235.4 |
193.4 |
|
881.2 |
|
Net profit, bln rub |
? |
|
7.90 |
107.5 |
209.5 |
153.7 |
197.9 |
|
668.6 |
|
|
OCF, bln rub |
? |
|
64.8 |
102.0 |
227.5 |
388.4 |
145.8 |
|
863.7 |
|
CAPEX, bln rub |
? |
|
10.7 |
12.5 |
13.2 |
2.40 |
9.10 |
|
37.2 |
|
FCF, bln rub |
? |
|
54.1 |
89.5 |
214.3 |
390.8 |
136.7 |
|
831.3 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
539.8 |
530.6 |
541.9 |
577.0 |
614.7 |
|
2 264 |
|
Cost of production, bln rub |
|
|
9.20 |
11.3 |
14.0 |
17.6 |
13.8 |
|
56.7 |
|
R&D, bln rub |
|
|
263.2 |
244.3 |
250.0 |
258.2 |
296.2 |
|
1 049 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Assets, bln rub |
|
|
3 688 |
3 890 |
4 266 |
4 632 |
4 906 |
|
4 906 |
|
Net Assets, bln rub |
? |
|
2 536 |
2 694 |
3 004 |
3 253 |
3 407 |
|
3 407 |
|
Debt, bln rub |
|
|
447.5 |
439.1 |
908.1 |
415.3 |
406.2 |
|
406.2 |
|
Cash, bln rub |
|
|
943.5 |
975.6 |
1 115 |
1 480 |
1 316 |
|
1 316 |
|
Net debt, bln rub |
|
|
-496.0 |
-536.5 |
-206.7 |
-1 065 |
-910.0 |
|
-910.0 |
|
|
Ordinary share price, rub |
|
|
110.6 |
125.7 |
140.4 |
141.8 |
131.7 |
|
167.3 |
|
Number of ordinary shares, mln |
|
|
99.7 |
99.0 |
99.4 |
99.5 |
100.5 |
|
100.5 |
|
|
Market cap, bln rub |
|
|
11 027 |
12 443 |
13 954 |
14 112 |
13 240 |
|
16 812 |
|
EV, bln rub |
? |
|
10 531 |
11 907 |
13 747 |
13 047 |
12 330 |
|
15 902 |
|
Book value, bln rub |
|
|
2 499 |
2 657 |
2 968 |
3 253 |
3 407 |
|
3 407 |
|
|
EPS, rub |
? |
|
0.08 |
1.09 |
2.11 |
1.54 |
1.97 |
|
6.65 |
|
FCF/share, rub |
|
|
0.54 |
0.90 |
2.16 |
3.93 |
1.36 |
|
8.27 |
|
BV/share, rub |
|
|
25.1 |
26.8 |
29.9 |
32.7 |
33.9 |
|
33.9 |
|
|
EBITDA margin, % |
? |
|
5.47% |
22.2% |
37.7% |
29.2% |
23.7% |
|
28.4% |
|
Net margin, % |
? |
|
1.38% |
15.6% |
26.4% |
19.1% |
24.3% |
|
21.6% |
|
FCF yield, % |
? |
|
4.46% |
4.25% |
4.25% |
5.31% |
6.28% |
|
4.94% |
|
ROE, % |
? |
|
12.1% |
12.9% |
14.2% |
14.7% |
19.6% |
|
19.6% |
|
ROA, % |
? |
|
8.29% |
8.95% |
10.0% |
10.3% |
13.6% |
|
13.6% |
|
|
P/E |
? |
|
36.1 |
35.7 |
32.6 |
29.5 |
19.8 |
|
25.1 |
|
P/FCF |
|
|
22.4 |
23.5 |
23.5 |
18.8 |
15.9 |
|
20.2 |
|
P/S |
? |
|
4.57 |
4.96 |
5.20 |
4.93 |
4.27 |
|
5.42 |
|
P/BV |
? |
|
4.41 |
4.68 |
4.70 |
4.34 |
3.89 |
|
4.93 |
|
EV/EBITDA |
? |
|
18.8 |
21.4 |
20.7 |
18.1 |
14.0 |
|
18.0 |
|
Debt/EBITDA |
|
|
-0.89 |
-0.96 |
-0.31 |
-1.48 |
-1.03 |
|
-1.03 |
|
|
R&D/CAPEX, % |
|
|
2 460% |
1 954% |
1 894% |
10 758% |
3 255% |
|
2 819% |
|
|
CAPEX/Revenue, % |
|
|
1.87% |
1.82% |
1.66% |
0.30% |
1.12% |
|
1.20% |
|
| Neurocrine Biosciences shareholders |
